The US Food and Drug Administration (FDA) has granted fast track designation to Moderna’s Covid-19 vaccine candidate, mRNA-1273.
This designation will expedite future reviews of the vaccine as it progresses into later-stage clinical trials. Moderna’s Covid-19 vaccine is currently in Phase I clinical trials, however, the FDA recently authorised the company to conduct a Phase II trial.
The company’s chief medical officer commented: “Fast track designation underscores the urgent need for a vaccine against the novel coronavirus.
“As we await the full set of clinical data from the NIAID-led Phase 1 study, we are actively preparing for our Phase II and Phase III clinical studies to continue learning about the potential of mRNA-1273 to protect against SARS-CoV-2,” the virus that causes Covid-19.
Moderna has received funding from BARDA and CEPI to date to support its accelerated Covid-19 vaccine development programme.
